what is tirzepatide derived from Insights into the Mechanism of Action of Tirzepatide: A Narrative Review Tirzepatide, a New Era of

Study Design TRIUMPH-1 (NCT05929066) was a randomized, double-blind, placebo-controlled trial that tested weekly subcutaneous retatrutide at 4 mg, 9 mg, and 12 mg against placebo over 80 weeks

People with diabetes, particularly severe diabetes, tend to lose less weight with GLP-1s than people without diabetes, so microdosing is less likely to be as effective, though their dose should only be increased as they tolerate it. George said that in her professional opinion, microdosing is a potential option for patients with smaller amounts of weight to lose or as a bridge to start, or wean off, regular GLP-1 medications

doi: 10.1124/pr.113.007724 113 TalbotJBianchiniFJNascimentoDCOliveiraRDSoutoFOPintoLGet al

Youre doing enough